How to Know Your Medspa Uses Real Botox®: 5 Essential Tips for Consumers
Dr. Elizabeth Littlefield, Medical Director of dermani MEDSPA®, a top 25 U.S. provider of Botox®, offers these essential tips to help you ensure that your medspa is using genuine Botox® and why it's crucial to do your homework:
1. Beware of Providers Who Call It 'Tox' or Other Generic Terms
One of the first red flags to watch out for is when a provider uses vague or generic terms like 'tox,' 'botulinum,' or other euphemisms instead of calling it Botox®. Botox® is a trademarked product manufactured exclusively by Allergan Aesthetics, and reputable medspas will use the correct name to identify the product.
Providers who shy away from using the trademarked term may be attempting to sell you an off-brand or counterfeit version of Botox®, which can pose serious risks to your health. Always make sure the treatment being offered is the real, FDA-approved Botox® from Allergan.
2. Do an Alle® Provider Search
One of the easiest ways to verify whether a medspa is offering genuine Botox® is by searching for the provider on the Alle® website. Alle® is Allergan's loyalty rewards program for Botox® and other Allergan products, and it only works with providers who are authorized to purchase and administer authentic Botox®.
If your medspa is listed on the Alle® site, it's a good sign that they are sourcing their Botox® directly from Allergan. If they are not listed, it's worth asking questions about where their product comes from—or reconsidering your choice of provider altogether.
3. Look for the Allergan Seal on Their Website
Reputable medspas that use authentic Botox® will often display the Allergan seal of approval on their website. This seal indicates that the provider is recognized by Allergan as an authorized distributor of their products.
When browsing a medspa's website, take a moment to check for this seal. It's a quick and easy way to validate their credibility and confirm that they are using the real deal.
4. Insist on Seeing the Botox® Vial and Lot Number
Before receiving your treatment, ask your provider to open the Botox® vial in front of you and show you the lot number on the packaging. Genuine Botox® comes in distinct vials with clear labeling, including the Allergan name and a specific lot number.
This transparency allows you to confirm that the product being used is authentic and fresh. If a provider is hesitant or refuses to show you the vial and lot number, this should be a major red flag.
5. Ask About Their Status with Allergan
Allergan recognizes its top-performing providers with specific designations based on the volume of Botox® they administer. Providers with a high status with Allergan have extensive experience and a proven track record of delivering authentic treatments.
Dr. Elizabeth Littlefield of dermani MEDSPA® emphasizes the importance of asking about a medspa's Allergan status:
'As a top 25 medical spa in the United States for Allergan, the only true maker of Botox®, we highly recommend that clients educate themselves by asking the right questions whenever they are considering who will be injecting Botox® into their body.'
By choosing a medspa with a strong relationship with Allergan, you can feel confident that you're receiving genuine Botox® from a provider who prioritizes safety and excellence.
Why It's Critical to Choose Real Botox®
Choosing a medspa that uses authentic Botox® is about more than just ensuring the best cosmetic results. Counterfeit or off-brand botulinum toxins can lead to serious health risks, including infections, allergic reactions, and unpredictable outcomes. Genuine Botox® from Allergan has undergone rigorous testing and is FDA-approved, making it a safe and effective option when administered by a qualified provider.
Final Thoughts
When it comes to Botox®, knowing your medspa uses the real product is essential for both safety and results. By following these five tips—avoiding vague terms like 'tox,' doing an Alle® search, checking for the Allergan seal, verifying the vial and lot number, and asking about Allergan status—you can confidently choose a provider who will deliver the quality and care you deserve.
dermani MEDSPA®
Sheanya Samuels
470-835-0183

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
Yahoo
40 minutes ago
- Yahoo
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging
Yahoo
an hour ago
- Yahoo
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies) New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the heart vessels Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a condition called atherosclerotic cardiovascular disease (ASCVD). 'For people living with diabetes and obesity, heart disease is one of the biggest threats that could change a person's life in an instant. Semaglutide is proven to reduce the risk of cardiovascular events by 20-26%1, meaning fewer hospitalisations, heart attacks, stroke and deaths,' said Ludovic Helfgott, executive vice president and head of Product & Portfolio Strategy at Novo Nordisk. The key role of cardiovascular inflammation in ASCVD will be discussed in a Novo Nordisk symposium on Saturday, 30 August. ASCVD is a condition where blood vessels that carry blood to your heart cut off the blood flow to other parts of your body, making those vessels stiff and narrow. Additionally, a range of real-world evidence is being presented, providing a thorough analysis of the impact of inflammation in cardiovascular disease on mortality and major cardiovascular events in people with ASCVD. Real-world evidence is data from everyday healthcare settings that show how treatments work in real life, beyond controlled clinical trials. 'At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the real world,' Ludovic Helfgott said. 'Semaglutide is unrivalled in the GLP-1 class with its proven reduction in heart attack, stroke, kidney complications and cardiovascular death.' Key Novo Nordisk data at the ESC congress 2025 include: Scientific Sessions: Unravelling cardiovascular inflammation in atherosclerotic cardiovascular disease (ASCVD): from evidence to guidance – Saturday 30 August; 10:00 – 10:45 CEST GLP-1RAs in obesity-related HFpEF: a new era in treatment – Sunday 31 August; 10:00 –10:45 CEST A change of heart – why cardiologists can't ignore semaglutide – Sunday 31 August; 12:30 – 13:30 CEST Poster and oral presentations:Ozempic® (once-weekly semaglutide 1.0 mg) Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age – Friday 29 August; 08:35 – 08:45 CEST STRIDE Outcomes by Sex – Sunday 31 August; 09:15 – 09:30 CEST Rybelsus® (once-daily oral semaglutide) Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial – Friday 29 August; 14:40 – 14:50 CEST Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis – Saturday 30 August; 08:33 – 08:51 CEST Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes – Monday 1 September; 13:15 – 14:00 CEST Wegovy® (once-weekly semaglutide 2.4 mg) Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial – Friday 29 August; 14:30 – 14:40 CEST Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice – Sunday 31 August; 09:00 – 09:15 CEST Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial – Sunday 31 August; 17:40 – 17:50 CEST Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial – Monday 1 September; 13:15 – 14:00 CEST Cardiovascular inflammation Associations between C-reactive protein levels and mortality in individuals with atherosclerotic cardiovascular disease and chronic kidney disease: results from the UK Discover database – Friday 29 August; 08:51 – 09:09 CEST Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease – Sunday 31 August; 08:45 – 08:55 CEST Direct healthcare costs for individuals with atherosclerotic cardiovascular disease, chronic kidney disease stages 3–4 or both: results from the UK Discover database – Monday 1 September; 14:15 – 15:00 CEST Awareness and perceptions on the role of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: a national study among cardiologists and nephrologists in China – Monday 1 September; 14:15 – 15:00 CEST General obesity Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the Swedish AROS study – Saturday 30 August; 10:15 – 11:00 CEST If you have any questions about the data or want more information, reach out to globalmedia@ About semaglutideSemaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that mimics the effects of the naturally occurring hormone GLP-1. It has been tested in several robust clinical development programmes and outcomes studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases1-8. Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide 14 mg)6-8. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Christoffer Sho Togo Tullin+45 3079 1471cftu@ Alex Bruce +45 34 44 26 13axeu@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121.3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.4. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-286.5. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392:2001-2012.6. Ozempic® (once-weekly semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025.7. Wegovy® (semaglutide injection 2.4 mg): Summary of Product Characteristics. Available at: Last accessed: August 2025.8. Rybelsus® (once-daily oral semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025. Attachment PR250820-Curtain-Raiser-ESC-2025